Cepheid (CPHD) Scheduled to Post Quarterly Earnings on Wednesday
Cepheid (NASDAQ:CPHD) will be announcing its earnings results after the market closes on Wednesday, October 12th. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Cepheid has set its FY16 guidance at $0.31-0.34 EPS.
Cepheid (NASDAQ:CPHD) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.19. Cepheid had a negative net margin of 8.78% and a negative return on equity of 10.20%. The company had revenue of $146 million for the quarter, compared to analysts’ expectations of $145.82 million. During the same period last year, the company earned ($0.06) EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, analysts expect Cepheid to post $0.33 EPS for the current fiscal year and $0.96 EPS for the next fiscal year.
Shares of Cepheid (NASDAQ:CPHD) opened at 52.84 on Tuesday. Cepheid has a 52-week low of $25.09 and a 52-week high of $53.91. The company has a 50 day moving average of $47.54 and a 200 day moving average of $35.72. The firm’s market capitalization is $3.86 billion.
In other news, VP Scott A. Campbell sold 746 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $36.71, for a total transaction of $27,385.66. Following the completion of the transaction, the vice president now directly owns 10,721 shares in the company, valued at $393,567.91. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 4.16% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Jefferies Group LLC acquired a new position in shares of Cepheid during the second quarter worth approximately $9,833,000. Mackenzie Financial Corp acquired a new position in shares of Cepheid during the second quarter worth approximately $7,337,000. Champlain Investment Partners LLC raised its position in shares of Cepheid by 6.9% in the second quarter. Champlain Investment Partners LLC now owns 3,436,980 shares of the company’s stock worth $105,687,000 after buying an additional 222,960 shares during the period. Grandeur Peak Global Advisors LLC acquired a new position in shares of Cepheid during the second quarter worth approximately $3,232,000. Finally, Spark Investment Management LLC raised its position in shares of Cepheid by 341.9% in the second quarter. Spark Investment Management LLC now owns 111,800 shares of the company’s stock worth $3,437,000 after buying an additional 86,500 shares during the period. Institutional investors own 95.27% of the company’s stock.
Several equities research analysts have commented on CPHD shares. Jefferies Group boosted their price target on shares of Cepheid from $28.00 to $34.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Cowen and Company cut shares of Cepheid from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 7th. Barclays PLC boosted their price target on shares of Cepheid from $36.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Wednesday, September 7th. Morgan Stanley started coverage on shares of Cepheid in a research report on Wednesday, June 15th. They issued an “equal weight” rating and a $30.00 price target on the stock. Finally, Robert W. Baird boosted their price target on shares of Cepheid from $44.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 7th. Seventeen analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $41.83.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Stock Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related stocks with our FREE daily email newsletter.